Core Insights - National Research Corporation (NRC) shares have declined 9.1% since the earnings report for Q4 2024, compared to a 0.6% decline in the S&P 500 index during the same period [1] - The company reported earnings per share of 28 cents for Q4 2024, down from 36 cents in the same quarter last year [2] - Revenues for Q4 2024 were $36.9 million, a decrease from $38 million in the prior-year quarter [2] - Net income fell to $6.6 million from $8.9 million year-over-year [2] Financial Performance - Total operating expenses increased to $27.3 million from $26.3 million, driven by higher direct expenses and selling, general, and administrative (SG&A) costs [3] - Operating income decreased to $9.6 million from $11.7 million, reflecting the impact of higher costs and lower revenues [3] - Interest expenses rose to $0.7 million from $0.3 million in the prior-year quarter [4] Business Metrics - Total recurring contract value was approximately $133.2 million as of December 31, 2024 [4] - Net indebtedness was around $58.5 million at the end of the quarter [4] Performance Influencers - Revenue declines and margin compression were key factors contributing to NRC's lower earnings performance [5] - A modest increase in operating expenses, particularly in SG&A costs, negatively impacted profitability [5] - A significant rise in interest expenses further pressured net income [5] Other Developments - NRC continued its capital allocation strategy through share repurchases and dividend distributions, repurchasing approximately 393,000 shares for around $7.3 million [6] - The company paid a quarterly dividend of 12 cents per share, totaling approximately $2.8 million [6]

Financial Performance - Revenue for Q4 2024 was approximately $36.9 million, a decrease of 2.9% compared to approximately $38.0 million in Q4 2023[3] - Earnings per diluted share for Q4 2024 were $0.28, down from $0.36 in Q4 2023, representing a decline of 22.2%[3] - Net income for Q4 2024 was $6.6 million, a decrease of 25.8% from $8.9 million in Q4 2023[8] - Total operating expenses for Q4 2024 were approximately $27.3 million, an increase of 3.9% compared to $26.3 million in Q4 2023[8] Shareholder Returns - The company returned approximately $10.1 million to shareholders through dividends and stock repurchases during the quarter[4] - The company repurchased approximately 393,000 shares for about $7.3 million and paid a regular quarterly dividend of $0.12 per share, totaling approximately $2.8 million[4] Contract Value and Debt - Total recurring contract value (TRCV) was approximately $133.2 million as of December 31, 2024[3] - The company's net indebtedness was approximately $58.5 million as of December 31, 2024[3] Assets and Equity - Total assets increased to $132.5 million as of December 31, 2024, compared to $122.4 million in 2023[10] - Shareholders' equity decreased to $31.3 million as of December 31, 2024, down from $49.0 million in 2023[10]

Core Insights - BTQ Technologies Corp. is set to receive funding of up to $150,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support its research and development project focused on secure quantum random number generation (QRNG) [5][6] - The project aims to develop distributed consensus algorithms for QRNG, which is essential for cryptography and various critical industries such as blockchain, telecommunications, and finance [1][6] - BTQ plans to pursue additional research and development funding and collaborations to enhance its presence in Canada's quantum and cybersecurity ecosystems [2] Company Overview - BTQ Technologies Corp. is a global quantum technology company that focuses on securing mission-critical networks and was founded by experts in post-quantum security [8] - The company has a strong technology portfolio and commercialization platform aimed at addressing security threats posed by large-scale quantum computers [8] - Olivier Roussy-Newton, the CEO and Chairman, expressed satisfaction with the support from NRC IRAP, highlighting the company's commitment to building its presence in the quantum ecosystem [7]

Core Viewpoint - Zacks Investment Research has initiated coverage of National Research Corporation (NRC) with a Neutral rating, highlighting both opportunities and challenges in the evolving healthcare landscape [1] Group 1: Competitive Position and Innovations - NRC Health has strengthened its competitive position through strategic partnerships and technological advancements, including collaborations with Cooper University Health Care and Medallia [2] - The company's AI-enabled tools, powered by its proprietary Huey engine, enhance its innovative edge, providing real-time feedback and actionable insights to healthcare organizations [3] - The acquisition of Nobl adds advanced rounding tools to NRC Health's portfolio, addressing the rising demand for technology-driven patient care solutions [3] Group 2: Financial Performance - NRC Health generated $28.2 million in operating cash flow during the first nine months of 2024, a 7% increase from the prior year [4] - Revenues for the first nine months of 2024 declined 4% year over year to $106.2 million, with recurring contract value dropping 9% [5] - Long-term debt increased to $48.7 million as of September 30, 2024, alongside a sharp rise in interest expenses, indicating heightened financial risk [5] Group 3: Market Position and Valuation - NRC Health's stock has faced significant downward pressure over the past year due to revenue declines and rising debt levels, trading at a discount to industry peers [6] - The current valuation leaves room for potential upside if NRC Health stabilizes its financial performance and capitalizes on strategic initiatives [6] - While innovative offerings position NRC Health to capitalize on the transition to value-based care, challenges such as declining revenues and intense competition weigh on the stock's near-term potential [7] Group 4: Market Capitalization - NRC Health has a modest market capitalization of $458.7 million, indicating its position in a promising but risky segment of the market [8]

Revenue Performance - Revenue for the three months ended September 30, 2024, decreased by $2.1 million (6%) to $35.8 million compared to $37.9 million in the same period of 2023, primarily due to decreased US recurring revenue from the existing client base[90] - For the nine months ended September 30, 2024, revenue decreased by $4.4 million (4%) to $106.2 million compared to $110.6 million in the same period of 2023, mainly from decreased US recurring revenue[96] - Recurring contract value declined by 9% to $131.6 million in 2024 compared to $144.3 million in 2023, primarily due to a lack of growth in new contracts[102] Expenses - Direct expenses increased by $1.1 million (5%) to $15.3 million in the three months ended September 30, 2024, mainly from higher conference expenses[90] - Selling, general, and administrative expenses decreased by $814,000 (7%) to $10.99 million in the three months ended September 30, 2024, primarily due to reduced marketing and consulting expenses[90] - Total other expense increased by $768,000, primarily due to lower interest income and higher interest expense, leading to a total other expense of $(684,000) in the three months ended September 30, 2024[94] Operating Income - Operating income for the three months ended September 30, 2024, decreased by $1.98 million (20%) to $7.98 million compared to $9.96 million in the same period of 2023[90] Cash Flow and Dividends - Cash provided by operating activities increased by $1.84 million (7%) to $28.2 million for the nine months ended September 30, 2024, compared to $26.4 million in the same period of 2023[96] - The company paid cash dividends of $8.6 million in the nine months ended September 30, 2024, with $2.8 million declared in the three months ended September 30, 2024[110] Debt and Credit Facilities - As of September 30, 2024, the company had $3.5 million in cash and cash equivalents, with up to $25 million of unused borrowings under the Line of Credit[104] - As of September 30, 2024, the outstanding balance on the Term Loan was $14.5 million, with monthly principal payments of $92,800 due through May 2027[115] - The outstanding balance on the Delayed Draw Term Loan was $34.2 million, with monthly principal payments of $220,882 due through May 2027[116] - The Line of Credit had $5.0 million of borrowings outstanding as of September 30, 2024, with an availability to borrow an additional $25.0 million[117] - The weighted average interest rate on borrowings on the Line of Credit for the three-month period ended September 30, 2024 was 7.65%[117] - The company is required to maintain a minimum fixed charge coverage ratio of 1.10x and a cash flow leverage ratio of 3.00x or less throughout the term of the Credit Facilities[119] - The company amended its Credit Facilities on August 5, 2024, revising the interest rate on the Term Loan to a floating rate based on the 30-day SOFR plus 235 basis points[114] - The company is obligated to pay ongoing unused commitment fees at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility[118] Stock Repurchase - During the three months ended September 30, 2024, the company repurchased 395,217 shares of common stock under the 2022 Stock Repurchase Program[125] - As of September 30, 2024, the remaining number of shares that could be purchased under the 2022 Program was 700,633 shares[125] Tax Liabilities - The company had a liability for gross unrecognized tax benefits related to uncertain tax positions amounting to $2.2 million as of September 30, 2024[122]

Financial Performance - Revenue for Q3 2024 was approximately $35.8 million, a decrease of 5.5% compared to $37.9 million in Q3 2023[2] - Earnings per diluted share were $0.24, down from $0.32 in the same quarter last year, representing a decline of 25%[2] - Net income for Q3 2024 was $5.7 million, compared to $7.9 million in Q3 2023, reflecting a decrease of 27.7%[6] - Total operating expenses for Q3 2024 were approximately $27.8 million, slightly down from $28.0 million in Q3 2023[6] Shareholder Returns - The company returned approximately $11.5 million to shareholders through dividends and stock repurchases during the quarter[3] - The regular quarterly dividend of $0.12 per share was declared, amounting to approximately $2.9 million[3] Contract Value and Debt - Total recurring contract value (TRCV) reached approximately $131.6 million as of September 30, 2024[2] - The company's net indebtedness was approximately $50.2 million as of September 30, 2024[2] Assets and Equity - Total assets increased to $131.8 million from $122.4 million at the end of 2023[7] - Shareholders' equity decreased to $34.6 million from $49.0 million at the end of 2023[7]

United States' approach to nuclear energy innovation. This legislation aims to modernize the NRC's licensing and regulatory practices to be more supportive of marketplace innovation. Within one year of enactment, the NRC must submit a report to Congress detailing specific improvements to nuclear reactor and materials oversight, emphasizing efficiency through risk-informed procedures, advanced technologies, and staff training. Additionally, the ADVANCE Act requires the NRC, in collaboration with the Departme ...

National Research Corporation [NRC] Q1 2024 Earnings Conference Call May 8, 2024 11:00 AM ET Company Participants Linda Stacy - VP, Finance Mark Scudder - ELT Helen Hrdy - CCO Operator Good morning or good afternoon all, and welcome to the National Research Corporation First quarter earnings call. My name is Adam, and I'll be your operator today. [Operator instructions]. I will now hand the floor to Linda Stacy to begin. So, Linda, please go ahead when you're ready. Linda Stacy Thank you, Adam, and welcome, ...

For the quarterly period ended March 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) Delaware 47- ...

Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact:Linda A. Stacy Principal Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER RESULTS LINCOLN, Nebraska (May 7, 2024) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Chief Executive Officer, commented: "NRC continues to be strongly positioned for growth in our expanding markets. O ...